Pfizer Stock Performance

PFE -  USA Stock  

USD 50.65  0.25  0.50%

Pfizer has performance score of 3 on a scale of 0 to 100. The company holds a Beta of 0.6545, which implies possible diversification benefits within a given portfolio. Let's try to break down what Pfizer's beta means in this case. As returns on the market increase, Pfizer returns are expected to increase less than the market. However, during the bear market, the loss on holding Pfizer will be expected to be smaller as well. Although it is extremely important to respect Pfizer Inc current trending patterns, it is better to be realistic regarding the information on equity existing price patterns. The philosophy towards forecasting future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By analyzing Pfizer Inc technical indicators, you can presently evaluate if the expected return of 0.0978% will be sustainable into the future. Pfizer Inc right now holds a risk of 1.87%. Please check Pfizer Inc total risk alpha, expected short fall, price action indicator, as well as the relationship between the value at risk and daily balance of power to decide if Pfizer Inc will be following its historical price patterns.
  
Refresh
Pfizer Performance
3 of 100
Compared to the overall equity markets, risk-adjusted returns on investments in Pfizer Inc are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound technical and fundamental indicators, Pfizer is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more

Pfizer Price Channel

Quick Ratio1.10
Fifty Two Week Low38.48
Target High Price75.00
Fifty Two Week High61.71
Payout Ratio35.36%
Trailing Annual Dividend Yield3.08%
Target Low Price49.00

Pfizer Relative Risk vs. Return Landscape

If you would invest  4,814  in Pfizer Inc on February 18, 2022 and sell it today you would earn a total of  251.00  from holding Pfizer Inc or generate 5.21% return on investment over 90 days. Pfizer Inc is generating 0.0978% of daily returns assuming volatility of 1.8671% on return distribution over 90 days investment horizon. In other words, 16% of stocks are less volatile than Pfizer, and above 99% of all equities are expected to generate higher returns over the next 90 days.
 Daily Expected Return (%) 
      Risk (%) 
Considering the 90-day investment horizon Pfizer is expected to generate 1.37 times more return on investment than the market. However, the company is 1.37 times more volatile than its market benchmark. It trades about 0.05 of its potential returns per unit of risk. The DOW is currently generating roughly -0.09 per unit of risk.

Pfizer Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Pfizer's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pfizer Inc, and traders can use it to determine the average amount a Pfizer's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0524

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
PFEHigh
Risk
Huge
Risk
Negative Returns
Estimated Market Risk
 1.87
  actual daily
 
 16 %
of total potential
 
1616
Expected Return
 0.1
  actual daily
 
 1 %
of total potential
 
11
Risk-Adjusted Return
 0.05
  actual daily
 
 3 %
of total potential
 
33
Based on monthly moving average Pfizer is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pfizer by adding it to a well-diversified portfolio.

About Pfizer Performance

To evaluate Pfizer Inc Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Pfizer generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Pfizer Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Pfizer Inc stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Pfizer's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and womens health under the Premarin family and Eliquis brands biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the ComirnatyBNT162b2, Nimenrix, FSMEIMMUN-TicoVac, Trumenba, and the Prevnar family brands biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, EucrisaStaquis, and Cibinqo brands and amyloidosis, hemophilia, and endocrine diseases under the VyndaqelVyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company Astellas Pharma US, Inc. Myovant Sciences Ltd. Akcea Therapeutics, Inc Merck KGaA Valneva SE BioNTech SE and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Things to note about Pfizer Inc

Checking the ongoing alerts about Pfizer for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Pfizer Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Pfizer Alerts

Equity Alerts and Improvement Suggestions

About 70.0% of the company shares are owned by institutional investors
Latest headline from www.fool.com: Acquisition by Jennifer Damico of tradable shares of Pfizer subject to Rule 16b-3
Please check Your Equity Center. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Pfizer Stock analysis

When running Pfizer Inc price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine Pfizer value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.